Tag: Patent Litigation

1
PTAB’s Motion to Amend Patentability Powers
2
German Constitutional Court partly slows down the Unified Patent Court Agreement Process
3
POP Provides Clarity Regarding Level of Proof for Printed Publications Before the PTAB
4
Producers of generic medicines and biosimilars even more supported by EU

PTAB’s Motion to Amend Patentability Powers

In a 2-1 split decision on Wednesday, July 22, 2020, the Federal Circuit confirmed that the Patent Trial and Appeal Board (“PTAB“) had the authority to reject substitute claims under 35 U.S.C. §§ 101 and 112, statutory grounds not available to the PTAB for evaluating patentability of granted patent claims in inter partes review (“IPR“). (Uniloc 2017 LLC, v. Hulu, LLC et al., Case No. 2019-1686, slip op. at 3 (Fed. Cir. July 22, 2020).)

Read More

German Constitutional Court partly slows down the Unified Patent Court Agreement Process

Today the German Federal Constitutional Court announced its decision in the complaint against the German implementation of the Unified Patent Court Agreement (UPCA). The outcome of the decision is a clear yes-and-no!

Read More

POP Provides Clarity Regarding Level of Proof for Printed Publications Before the PTAB

The PTAB’s Precedential Opinion Panel (“POP”) issued a decision in Hulu, LLC v. Sound View Innovations, LLC, IPR2018-01039, on Friday, December 20, 2019. The issue at hand: “What is required for a petitioner to establish that an asserted reference qualifies as ‘printed publication’ at the institution stage?” Hulu v. Sound View, IPR2018-01039, Paper 29 at *2 (P.T.A.B. December 20, 2019).

This decision provides clarity on an issue that was often addressed inconsistently across panels regarding the “requirements for institution involving issues of public accessibility of an asserted ‘printed publication.’” Id. at 2.

Read More

Producers of generic medicines and biosimilars even more supported by EU

Effective 1 July 2019, the EU adopted a regulation by introducing a supplementary protection certificate (SPC) manufacturing and stockpiling waiver. This waiver also applies for biosimilar versions of SPC-protected medicine during the term of the SPC.

Read More

Copyright © 2019, K&L Gates LLP. All Rights Reserved.